Máyla entered the fight to control the Spanish medical cannabis market

The Spanish laboratory Mayla will soon launch Canabiben, a product containing cannabidiol (CBD) which acts as an anti-inflammatory and relaxing substance. In this way, Mayla entered the competition to control medical cannabis.

The product will be launched during February this year and will come in two different presentations: in cream and capsules, both with the same name. The cream, which will be sold in a 60-milligram format, contains Cannabidiol (CBD), which acts as an anti-inflammatory and relaxing substance. In addition, it includes Harpagophytum and Arnica extracts, which among other functions serve as decongestants, and calmatives.

The capsules will be sold in a box containing two blister packs of fifteen pills each. These tablets are composed of Cannabis Sativa Oil, which acts as an anti-inflammatory, cinnamon extract, and vitamins B1, B6, B12, E, and D3.

Hemp.im mobile app is the most trusted source for cannabis news, and investment tips in the thriving cannabis industry.

Distribution of products exclusively through pharmacies

The unit sales price of the cream will be $8.16 (€7.5), and a box with capsules will cost $12.52 (€11.5). With both products, pharmacies will have a profit margin of 44%, according to industry sources. In addition, the laboratory offers pharmacies the possibility of acquiring a promotional display containing five units of each presentation at a laboratory sales price of $83 (€76) and with the same profit margin.

Máyla is based in Barcelona and distributes its products exclusively through pharmacies, with a presence throughout Spain. The company is also present in several countries in Asia and America.

$3,6 million profit in 2018

Mayla CEO is Eugen Antohi, who has been in charge since the company’s founding in 2012. Previously, he led the consumer healthcare area at A&D Pharma and was responsible for Romania, Bulgaria, Ukraine, and Spain at Walmark, another company that manufactures and distributes consumer healthcare products.

The laboratory earned $3.6 million (€3.3 million) in 2018, 14.8% less than the previous year, when it had a turnover of $4.2 million (€3.9 million), according to the latest accounts available in the commercial register. The company recorded a loss of $ 623.006 (€572.645) in 2018.

Cannabidiol (CBD) less known than tetrahydrocannabinol (THC)

Cannabis has been popular so far for its psychoactive and narcotic properties. These effects are produced by one of its components, tetrahydrocannabinol (THC), which in addition to altering people’s brain has also proved to be very effective in the treatment of diseases such as multiple sclerosis or epilepsy. In fact, Almirall markets in Spain a THC-based drug for multiple sclerosis called Sativex.

However, it is less known that cannabis contains cannabidiol (CBD), a component that has no psychoactive effect and yet has multiple therapeutic properties. Cannabiben bases its efficacy on precisely this compound, as does Cannabix sold by Uriach.

The sale of CBD-containing products has become a great business opportunity. The Cannabix exceeded all Uriach’s expectations by billing in the first two months of life what the pharmaceutical company had planned for the whole year.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce., a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.